Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

The global liquid biopsy market size was valued at USD 10.99 billion in 2024 and is projected to reach from USD 12.23 billion ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...